While combination anti-TNF/TNFR therapeutics have the potential to improve clinical response rates over traditional therapeutics, such combinations should be approached with caution due to the potential for additive immunosuppression that affects both innate and adaptive immunity and increased vulnerability to opportunistic infections. The gene discussed is TNF; the disease is Opportunistic infection.